Hemostatic Disorder Clinical Trial
Official title:
Hemostatic Disorders Impact on Intensive Care Patients.
1. To assess the incidence of hemostatic disorders among ICU patients.
2. To establish a relationship between supportive treatment and survival in patients with
coagulopathy in ICU.
3. To provide solutions that can help in reduction of the incidence of hemostatic disorders
in ICU patients.
Hemostasis is the physiological process that stops bleeding at the site of an injury while
maintaining normal blood flow elsewhere in the circulation. Blood loss is stopped by
formation of a hemostatic plug. The endothelium in blood vessels maintains an anticoagulant
surface that serves to maintain blood in its fluid state, but if the blood vessel is damaged
components of the subendothelial matrix are exposed to the blood. Several of these components
activate the two main processes of hemostasis to initiate formation of a blood clot, composed
primarily of platelets and fibrin.
Many critically ill patients develop hemostatic abnormalities, ranging from isolated
thrombocytopenia to complex defects, such as DIC. Coagulation abnormalities are commonly
found in critically ill patients. Prompt and proper identification of the underlying cause of
these coagulation abnormalities is required, since each coagulation disorder necessitates
very different therapeutic management strategies.
Management of coagulopathy The key basic management principle of all coagulopathies is that
the decision to transfuse blood products should not be based on the results of coagulation
tests alone, rather an individualized approach is warranted. It is imperative to synthesizes
all the available clinical data and treat the underlying cause.
In summary, hemostatic disorders are very common in the critically ill. Blood product support
is frequently required, but there is only a very limited evidence-base to support its use. In
many cases, no specific product support is required and the key management step is the
treatment of the condition underlying the coagulopathy .
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05775731 -
Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
|
||
| Recruiting |
NCT04600609 -
Examining the Experiences of Children With Blood Disorders
|
||
| Active, not recruiting |
NCT04309084 -
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT04757285 -
Copeptin and Psychological Stress of Medic During COVID-19 Pandemic
|
||
| Terminated |
NCT04729946 -
Clinical and Urgent Colonoscopy Outcomes Using the Pure-Vu® Cleansing System
|
N/A | |
| Not yet recruiting |
NCT06242353 -
Coagulopathy in Childhood Acute Lymphoblastic Leukaemia
|
||
| Completed |
NCT04499612 -
Influence of Cardiac Implantable Electronic Devices on the Hemostatic System
|
||
| Not yet recruiting |
NCT06328647 -
Quantra Point-of-Care Hemostasis Monitoring
|
N/A | |
| Recruiting |
NCT04650529 -
Gyeongsang National University Hospital Registry
|
||
| Completed |
NCT03756948 -
Viscoelastic Tests-Guided Therapy In Liver Transplantation
|
N/A | |
| Recruiting |
NCT05476458 -
To Evaluate Efficacy of Red Dichromatic Imaging (RDI) in Achieving Hemostasis During POEM Using GF 1500 UGI Scope
|
||
| Recruiting |
NCT04762576 -
Thrombin in Cardiac Surgery
|
||
| Completed |
NCT03555383 -
Individualized Multimodal Hemostasis Evaluation Pyramid (IMHOTEP)
|
||
| Terminated |
NCT03806556 -
A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03281252 -
A Prospective Study of Evaluation of Minor Bleeding and Utility of Bleeding Criteria in Acute-on-chronic Liver Failure Patients in China
|
N/A |